Which HPV vaccine is recommended, the bivalent or the nonavalent?
Feb 02, 2023
Source: Cainiu Health
Dr. Zhao Xiaodong
Introduction
Both the bivalent and nonavalent HPV vaccines refer to cervical cancer vaccines. Receiving the cervical cancer vaccine can effectively prevent cancers caused by human papillomavirus (HPV). The appropriate vaccine is generally selected based on age and specific needs to achieve optimal preventive effects. The bivalent, quadrivalent, and nonavalent HPV vaccines differ in their immunogenicity.
Both the bivalent HPV vaccine and the nonavalent HPV vaccine refer to cervical cancer vaccines. Receiving a cervical cancer vaccine can effectively prevent cancers caused by human papillomavirus (HPV). The appropriate vaccine is generally selected based on age and individual needs to achieve optimal preventive effects. Specific details are as follows:
The bivalent HPV vaccine, quadrivalent HPV vaccine, and nonavalent HPV vaccine show no difference in immunogenicity or in their efficacy and effectiveness against cervical cancers related to HPV types 16 and 18. All three vaccines can prevent the majority of cervical cancers. The nonavalent HPV vaccine offers additional protection against five more high-risk HPV types (31, 33, 45, 52, and 58) compared to the quadrivalent vaccine, preventing approximately 5% more cervical cancer cases than the bivalent and quadrivalent HPV vaccines. Currently in China, the eligible age ranges for these three vaccines differ, so women can choose according to their age. The bivalent and quadrivalent HPV vaccines together can prevent over 70% of cervical cancers, providing a solid baseline of protection.
In addition to HPV vaccination, regular cervical cancer screening remains extremely important for prevention. This is especially true for women over 45 years old. Early detection, early diagnosis, and early treatment represent the best preventive strategy.
